lactobacillus acidophilus klds1.0901

Lactobacillus acidophilus KLDS1.0901 is a specific probiotic bacterial strain isolated from traditional fermented dairy foods in Sinkiang Province, China, and preserved at the Key Laboratory of Dairy Science, Northeast Agricultural University (Harbin, China)[5]. This live biotherapeutic product has demonstrated multiple health-promoting effects in preclinical studies: - **Metabolic and Liver Health:** In animal models, L. acidophilus KLDS1.0901 administration protected against high-fat diet-induced non-alcoholic fatty liver disease (NAFLD) by improving liver characteristics and modulating gut microbiota composition[1]. It also reduced serum lipopolysaccharide (LPS) and D-lactic acid levels—markers of intestinal barrier damage—and upregulated tight junction proteins such as occludin, claudin-1, ZO-1, and Muc-2 to enhance gut barrier integrity[1]. - **Diabetes:** The strain alleviated type 2 diabetes symptoms in mice by regulating hepatic glucose and lipid metabolism genes (downregulating GSK-3β, FAS, SREBP-1c; upregulating Akt), reducing inflammatory cytokines (IL-8, TNF-alpha, IL-1β), preventing tissue injury in the liver/colon[4], reshaping gut microbiota toward increased short-chain fatty acids production while decreasing harmful Gram-negative bacteria. - **Anti-inflammatory Effects:** L. acidophilus KLDS 1.0901 suppressed pro-inflammatory gene expression (TNF-alpha, IL-6, IL-1β), inhibited iNOS/COX2 expression and NO/PGE2 production via inhibition of TLR4-mediated NF-kappaB/MAPK signaling pathways in cell models[5]. These findings suggest its potential as a functional probiotic for metabolic disorders such as NAFLD and type 2 diabetes.

Other names

l. acidophilus klds1.0901